[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS54875B1 - Liofilizovane formulacije fgf-18 - Google Patents

Liofilizovane formulacije fgf-18

Info

Publication number
RS54875B1
RS54875B1 RS20160453A RSP20160453A RS54875B1 RS 54875 B1 RS54875 B1 RS 54875B1 RS 20160453 A RS20160453 A RS 20160453A RS P20160453 A RSP20160453 A RS P20160453A RS 54875 B1 RS54875 B1 RS 54875B1
Authority
RS
Serbia
Prior art keywords
fgf
freeze
dried formulations
formulations
dried
Prior art date
Application number
RS20160453A
Other languages
English (en)
Inventor
Alessandra Cerreti
Rio Alessandra Del
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of RS54875B1 publication Critical patent/RS54875B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Stabilna liofilizovana formulacija koja uključuje FGF-18, fosfatni pufer koji čini da vrednost pH ostane na između 7,0 i 7,5, poloksamer 188 i saharoza.Prijava sadrži još 11 patentnih zahteva.
RS20160453A 2011-06-17 2012-06-15 Liofilizovane formulacije fgf-18 RS54875B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21
PCT/EP2012/061495 WO2012172072A1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18
EP12728509.6A EP2720710B1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18

Publications (1)

Publication Number Publication Date
RS54875B1 true RS54875B1 (sr) 2016-10-31

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160453A RS54875B1 (sr) 2011-06-17 2012-06-15 Liofilizovane formulacije fgf-18

Country Status (32)

Country Link
US (2) US9326944B2 (sr)
EP (2) EP2720710B1 (sr)
JP (1) JP5981538B2 (sr)
KR (1) KR102019520B1 (sr)
CN (2) CN107715104A (sr)
AR (1) AR086956A1 (sr)
AU (1) AU2012268987B2 (sr)
BR (1) BR112013032400B1 (sr)
CA (1) CA2836667C (sr)
CL (1) CL2013003618A1 (sr)
CO (1) CO6940377A2 (sr)
CY (1) CY1117933T1 (sr)
DK (1) DK2720710T3 (sr)
EA (1) EA024937B1 (sr)
EC (1) ECSP14013157A (sr)
ES (1) ES2575732T3 (sr)
HR (1) HRP20160566T1 (sr)
HU (1) HUE028355T2 (sr)
IL (1) IL229977A (sr)
MX (1) MX338017B (sr)
MY (1) MY170630A (sr)
PE (1) PE20141265A1 (sr)
PH (1) PH12013502529A1 (sr)
PL (1) PL2720710T3 (sr)
PT (1) PT2720710E (sr)
RS (1) RS54875B1 (sr)
SG (1) SG195021A1 (sr)
SI (1) SI2720710T1 (sr)
TW (1) TWI527590B (sr)
UA (1) UA113174C2 (sr)
WO (1) WO2012172072A1 (sr)
ZA (1) ZA201308698B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
WO2015097236A2 (en) * 2013-12-24 2015-07-02 Ares Trading S.A Fgf-18 formulation in alginate/collagen hydrogels
MX2018001816A (es) * 2015-08-13 2018-05-16 Merck Patent Gmbh Composicion combinada que comprende el compuesto fgf-18.
CA3075722A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Extended release formulations for intra-articular applications
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法
CN118310835A (zh) * 2024-04-16 2024-07-09 杭州百凌生物科技有限公司 一种质控品冻干粉及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
NZ500539A (en) * 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
EP0931148B1 (en) * 1996-10-16 2006-03-01 ZymoGenetics, Inc. Fibroblast growth factor homologs
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
WO2000021548A2 (en) 1998-10-13 2000-04-20 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
EP1234033B1 (en) 1999-12-02 2011-12-28 ZymoGenetics, Inc. Methods for targeting cells that express fibroblast growth factor receptor-3 or-2
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
CA2500742C (en) 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
ES2381674T3 (es) * 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
EP3061461A1 (en) * 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
PL1828239T3 (pl) * 2004-12-10 2012-01-31 Zymogenetics Inc Produkcja FGF18 w organizmach prokariotycznych
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
CA2641588C (en) 2006-02-07 2014-06-17 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
EP2054050B1 (en) 2006-08-25 2012-08-08 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
SI2068909T1 (sl) * 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
ES2385114T3 (es) * 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
PT2720710E (pt) 2016-06-17
MX2013014894A (es) 2014-09-01
ES2575732T3 (es) 2016-06-30
MX338017B (es) 2016-03-29
EP2720710B1 (en) 2016-03-23
ECSP14013157A (es) 2014-02-28
NZ617992A (en) 2015-09-25
BR112013032400B1 (pt) 2021-07-20
CO6940377A2 (es) 2014-05-09
DK2720710T3 (en) 2016-06-27
KR20140041600A (ko) 2014-04-04
EP2720710A1 (en) 2014-04-23
UA113174C2 (xx) 2016-12-26
HRP20160566T1 (hr) 2016-06-17
HUE028355T2 (en) 2016-12-28
US9326944B2 (en) 2016-05-03
CN103619347A (zh) 2014-03-05
CA2836667C (en) 2020-01-14
EA024937B1 (ru) 2016-11-30
EA201490032A1 (ru) 2014-05-30
WO2012172072A1 (en) 2012-12-20
EP3056211A1 (en) 2016-08-17
CN107715104A (zh) 2018-02-23
SG195021A1 (en) 2013-12-30
JP5981538B2 (ja) 2016-08-31
AU2012268987B2 (en) 2016-09-08
JP2014522807A (ja) 2014-09-08
PH12013502529A1 (en) 2014-01-27
ZA201308698B (en) 2016-02-24
AR086956A1 (es) 2014-02-05
CY1117933T1 (el) 2017-05-17
TWI527590B (zh) 2016-04-01
CA2836667A1 (en) 2012-12-20
US20160228374A1 (en) 2016-08-11
SI2720710T1 (sl) 2016-07-29
TW201302217A (zh) 2013-01-16
BR112013032400A2 (pt) 2016-11-22
PE20141265A1 (es) 2014-09-29
PL2720710T3 (pl) 2016-09-30
CL2013003618A1 (es) 2014-07-04
MY170630A (en) 2019-08-21
KR102019520B1 (ko) 2019-11-04
IL229977A (en) 2017-01-31
US20140121162A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
RS54875B1 (sr) Liofilizovane formulacije fgf-18
BR112018005316A2 (pt) ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
BR112015025854A2 (pt) flagelina de roseburia e modulação imunológica
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
FR2998570B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MX2019007187A (es) Composiciones para el cuidado bucal.
CO6280406A2 (es) Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
EP2780014A4 (en) MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780013A4 (en) MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
BR112012019190A2 (pt) composições de cuidado oral.
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112012019997A2 (pt) composições de cuidado oral
EP2994142A4 (en) Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
BR112012023910A2 (pt) preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol
MX350170B (es) Composición inmunogénica estable de antígenos de staphylococcus aureus.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112015004515A2 (pt) composição imunogênica
BR112018010945A2 (pt) formulações com degradação de polissorbato reduzida